These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15886298)

  • 21. Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.
    Yoon JH; Kim JK; Rha GB; Oh M; Park SH; Seong RH; Hong SH; Park SD
    Biochem J; 1999 Dec; 344 Pt 2(Pt 2):367-74. PubMed ID: 10567217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the inverted CCAAT box 2 in the topoisomerase IIalpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies.
    Henry JA; Le NM; Nguyen B; Howard CM; Bailey SL; Horick SM; Buchmueller KL; Kotecha M; Hochhauser D; Hartley JA; Wilson WD; Lee M
    Biochemistry; 2004 Sep; 43(38):12249-57. PubMed ID: 15379563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
    Mo YY; Wang Q; Beck WT
    Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.
    Saxena D; Yiu GK; Ni X; Huang KC; Mantovani R; Jacquemin-Sablon AG; Ng SW
    Gene; 2004 Nov; 342(1):145-55. PubMed ID: 15527974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
    Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
    Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
    Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
    Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
    Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatostatin elevates topoisomerase II alpha and enhances the cytotoxic effect of doxorubicin on gallbladder cancer cells.
    Quan ZW; Yue JN; Li JY; Qin YY; Guo RS; Li SG
    Chemotherapy; 2008; 54(6):431-7. PubMed ID: 18824850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.
    Zhou RR; Jia SF; Zhou Z; Wang Y; Bucana CD; Kleinerman ES
    Cancer Gene Ther; 2002 May; 9(5):407-13. PubMed ID: 11961663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
    Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
    Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
    Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
    Mattila R; Alanen K; Syrjänen S
    Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
    Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
    Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
    Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
    Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.
    Wang YH; Takanashi M; Tsuji K; Tanaka N; Shiseki M; Mori N; Motoji T
    Leuk Res; 2009 Jul; 33(7):902-7. PubMed ID: 19185918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamics of human DNA topoisomerases IIalpha and IIbeta in living cells.
    Christensen MO; Larsen MK; Barthelmes HU; Hock R; Andersen CL; Kjeldsen E; Knudsen BR; Westergaard O; Boege F; Mielke C
    J Cell Biol; 2002 Apr; 157(1):31-44. PubMed ID: 11927602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.